Exosome-sheathed ROS-responsive nanogel to improve targeted therapy in perimenopausal depression

J Nanobiotechnology. 2023 Aug 8;21(1):261. doi: 10.1186/s12951-023-02005-y.

Abstract

The development of natural membranes as coatings for nanoparticles to traverse the blood-brain barrier (BBB) presents an effective approach for treating central nervous system (CNS) disorders. In this study, we have designed a nanogel loaded with PACAP and estrogen (E2), sheathed with exosomes and responsive to reactive oxygen species (ROS), denoted as HA NGs@exosomes. The objective of this novel design is to serve as a potent drug carrier for the targeted treatment of perimenopausal depression. The efficient cellular uptake and BBB penetration of HA NGs@exosomes has been demonstrated in vitro and in vivo. Following intranasal intervention with HA NGs@exosomes, ovariectomized mice under chronic unpredictable mild stress (CUMS) have shown improved behavioral performance, indicating that HA NGs@exosomes produced a rapid-onset antidepressant effect. Moreover, HA NGs@exosomes exhibit notable antioxidant and anti-inflammatory properties and may regulate the expression of pivotal proteins in the PACAP/PAC1 pathway to promote synaptic plasticity. Our results serve as a proof-of-concept for the utility of exosome-sheathed ROS-responsive nanogel as a promising drug carrier for the treatment of perimenopausal depression.

Keywords: Estrogen; Exosome; Nanogel; PACAP; Perimenopausal Depression.

MeSH terms

  • Animals
  • Depression* / drug therapy
  • Depression* / metabolism
  • Drug Carriers / metabolism
  • Exosomes* / metabolism
  • Mice
  • Nanogels
  • Perimenopause / metabolism
  • Pituitary Adenylate Cyclase-Activating Polypeptide / metabolism
  • Reactive Oxygen Species / metabolism

Substances

  • polyethylene glycol polyethyleneimine nanogel
  • Nanogels
  • Reactive Oxygen Species
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Drug Carriers